Neutrophil and monocyte beta 2-integrin expression in trisomic fetuses

Area of Science:

• Immunology
• Genetics
• Fetal Development

Background:

• Trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome) are common aneuploidies associated with immune system dysfunction.
• Beta 2-integrins are crucial for immune cell function, and their expression may be altered in chromosomal abnormalities.
• Understanding the molecular basis of immune deficiencies in aneuploidies is important for prenatal and postnatal care.

Purpose of the Study:

• To investigate beta 2-integrin expression on neutrophils and monocytes in fetuses with trisomy 21 and trisomy 18.
• To compare these expression levels with those in chromosomally normal fetuses.
• To determine if altered beta 2-integrin expression contributes to immune deficiencies observed in trisomies.

Main Methods:

• Flow cytometry was utilized to quantify beta 2-integrin expression.
• Samples were obtained from 7 fetuses with trisomy 18, 7 fetuses with trisomy 21, and 112 chromosomally normal fetuses.
• Gestation ranged from 20-25 weeks.

Main Results:

• No significant differences in beta 2-integrin expression were found on neutrophils and monocytes.
• Expression levels were comparable between normal fetuses and those with trisomy 18 or trisomy 21.
• These findings were consistent across both cell types and aneuploidies.

Conclusions:

• Altered beta 2-integrin expression is unlikely to be a pathogenic factor in the immunological deficiencies associated with trisomy 21 and trisomy 18.
• The study provides insights into the molecular mechanisms underlying immune dysfunction in these conditions.
• Further research may explore other immune system components in aneuploid fetuses.